Abstract PR-3: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Mol Cancer Ther (2011) 10 (11_Supplement): PR-3.
Currently there are no citedby results. Try again later.
